Premium
[O2–17–05]: RATIONALE FOR CNP520 DOSE SELECTION FOR THE PIVOTAL CLINICAL PROGRAM IN PRECLINICAL AD
Author(s) -
LopezLopez Cristina,
Ufer Mike,
RouzadeDominguez MarieLaure,
Pezous Nicole,
David Olivier,
Kolly Carine,
Tariot Pierre,
Reiman Eric M.,
Vargas Gabriel,
Lenz Robert,
Graf Ana,
Neumann Ulf
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.245
Subject(s) - tolerability , medicine , limiting , pharmacokinetics , adverse effect , pharmacology , safety pharmacology , drug , mechanical engineering , engineering